Effects of ditazol on the vascular retinal pattern in experimental diabetes in rats.

Abstract

Platelets from diabetic patients are hypersensitive to aggregating agents. An imbalance in thromboxane/prostacyclin synthesis has been postulated as an antecedent to the development of diabetic retinopathy. We studied 3-month streptozotocin-diabetic rats (SDR) treated with 200 mg/kg/day p.o. of ditazol, an antiplatelet drug that inhibits thromoboxane formation. Thromboxane B2 (TxB2) production was higher and 6-keto-PGF1 alpha synthesis lower in SDR than nondiabetic rats (NDR). In treated animals, ditazol inhibited platelet aggregation by 66%, and TxB2 production by 58%, and increased vascular 6-keto-PGF 1 alpha by 45%. Furthermore, 13% of the retinal surface was covered by peroxidase-labelled vessels in NDR, 2.1% in nontreated SDR, and 8.9% in SDR treated with ditazol. We postulate that ditazol may prevent or reduce diabetic retinopathy.

• Authors: A Moreno, J P De La Cruz, F Mérida, J García Campos, F Sánchez de la Cuesta
• Journal: Haemostasis (Haemostasis) 1995 Jul-Aug Vol. 25 Issue 4 Pg. 166-71 ISSN: 0301-0147 [Print] Switzerland
• PMID: 7557655 (Publication Type: Journal Article)

Chemical References

• Oxazoles
• Platelet Aggregation Inhibitors
• Thromboxane B2
• Epoprostenol
• ditazol
• Aspirin

Topics

• Animals
• Aorta, Abdominal (metabolism)
• Aspirin (pharmacology)
• Blood Platelets (metabolism)
• Diabetes Mellitus, Experimental (blood, complications)
• Diabetic Retinopathy (blood, etiology, prevention & control)
• Drug Evaluation, Preclinical
• Epoprostenol (biosynthesis)
• Male
• Oxazoles (pharmacology)
• Platelet Aggregation (drug effects)
• Platelet Aggregation Inhibitors (pharmacology)
• Rats
• Rats, Wistar
• Retinal Vessels (drug effects)
• Thromboxane B2 (biosynthesis)